ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action – Investors Notified to Contact BFA Law

ADMA Biologics is accused in a securities fraud class action of making misrepresentations about its revenue sources, prompting investor notification to contact counsel. The allegation raises credibility and financial-reporting risk, which is typically treated as a negative overhang for the stock pending case developments.

Analysis

ADMA Biologics is accused in a securities fraud class action of making misrepresentations about its revenue sources, prompting investor notification to contact counsel. The allegation raises credibility and financial-reporting risk, which is typically treated as a negative overhang for the stock pending case developments.